Blockade of the mineralocorticoid receptor improves markers of human endothelial cell dysfunction and hematological indices in a mouse model of sickle cell disease
The FASEB Journal · 2023-08 · 37 (8)
DOI: 10.1096/fj.202300671r ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The FASEB Journal, online erschienen am 21.07.2023. Verfasst von Alicia Rivera und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Vascular Biology Research Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Bosto…. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Vascular Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Increased endothelin‐1 (ET‐1) levels in patients with sickle cell disease (SCD) and transgenic mouse models of SCD contribute to disordered hematological, vascular, and inflammatory responses. Mineralocorticoid receptor (MR) activation by aldosterone, a critical component of the Renin‐Angiotensin‐Aldosterone‐System, modulates inflammation and vascular reactivity, partly through increased ET‐1 expression. However, the role of MR in SCD remains unclear. We hypothesized that MR blockade in transgenic SCD mice would reduce ET‐1 levels, improve hematological parameters, and reduce inflammation. Berkeley SCD (BERK) mice, a model of severe SCD, were randomized to either sickle standard chow or chow containing the MR antagonist (MRA), eplerenone (156 mg/Kg), for 14 days. We found that MRA treatment reduced ET‐1 plasma levels ( p = .04), improved red cell density gradient profile (D 50 ; p < .002), and increased mean corpuscular volume in both erythrocytes ( p < .02) and reticulocytes ( p < .024). MRA treatment also reduced the activity of the erythroid intermediate‐conductance Ca 2+ ‐activated K + channel – K Ca 3.1 (Gardos channel, KCNN4 ), reduced cardiac levels of mRNAs encoding ET‐1, Tumor Necrosis Factor Receptor‐1, and protein disulfide isomerase (PDI) ( p < .01), and decreased plasma PDI and myeloperoxidase activity. Aldosterone (10 −8 M for 24 h in vitro) also increased PDI mRNA levels ( p < .01) and activity ( p < .003) in EA.hy926 human endothelial cells, in a manner blocked by pre‐incubation with the MRA canrenoic acid (1 μM; p < .001). Our results suggest a novel role for MR activation in SCD that may exacerbate SCD pathophysiology and clinical complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Vascular Biology Research Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
- Departments of Laboratory Medicine and Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Quest Diagnostics, Secaucus, New Jersey, USA.
ORCID-Profile: Alicia Rivera, Seth L Alper, Jose R Romero
Förderung
- NHLBI NIH HHS
Zitieren
APA
Rivera, A., Vega, C., Ramos-Rivera, A., Maldonado, E. R., Prado, G. N., Karnes, H. E., Fesko, Y. A., Snyder, L. M., Alper, S. L., & Romero, J. R. (2023). Blockade of the mineralocorticoid receptor improves markers of human endothelial cell dysfunction and hematological indices in a mouse model of sickle cell disease. The FASEB Journal, 37(8). https://doi.org/10.1096/fj.202300671r
Vancouver
Rivera A, Vega C, Ramos-Rivera A, Maldonado ER, Prado GN, Karnes HE, et al. Blockade of the mineralocorticoid receptor improves markers of human endothelial cell dysfunction and hematological indices in a mouse model of sickle cell disease. The FASEB Journal. 2023;37(8). doi:10.1096/fj.202300671r
BibTeX
@article{Rivera2023,
author = {Rivera, Alicia and Vega, Christopher and Ramos-Rivera, Arelys and Maldonado, Enrique R and Prado, Gregory N and Karnes, Hope E and Fesko, Yuri A and Snyder, L Michael and Alper, Seth L and Romero, Jose R},
title = {Blockade of the mineralocorticoid receptor improves markers of human endothelial cell dysfunction and hematological indices in a mouse model of sickle cell disease},
journal = {The FASEB Journal},
year = {2023},
volume = {37},
number = {8},
doi = {10.1096/fj.202300671r}
}
EUVIMED